Andreas Storsve 8/30/23 Andreas Storsve 8/30/23

DoMore Diagnostics And Proscia Partner To Inform Personalized Treatment Decisions For Colorectal Cancer Patients

OSLO and PHILADELPHIA – August 30, 2023 – DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help pathologists predict outcomes for colorectal cancer (CRC) patients. The collaboration paves the way for integrating artificial intelligence (AI)-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care.

Spiros Kotopoulis 8/9/23 Spiros Kotopoulis 8/9/23

DoMore Diagnostics and The Ohio State University Wexner Medical Center to Collaborate on Digital Biomarker Histotype Px® Colorectal to Personalize Cancer Treatment

Under this agreement, The Ohio State University Wexner Medical Center will implement and validate DoMore Diagnostics' Histotype Px® Colorectal digital biomarker in a group of U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and stage III colorectal cancer.

Spiros Kotopoulis 6/1/23 Spiros Kotopoulis 6/1/23

DoMore Diagnostics welcomes Andreas Berg Storsve as our new VP Operations

DoMore Diagnostics is pleased to announce the appointment of Andreas Berg Storsve, PhD as VP Operations. Dr. Storsve will join the management team and take a leading role in driving partnerships and business development activities forward.

Spiros Kotopoulis 1/23/23 Spiros Kotopoulis 1/23/23

DoMore Diagnostics has successfully completed ISO 13485 certification

DoMore Diagnostics today announced that the quality management system (QMS) has been certified as compliant with the ISO 13485 standard. The certification audit process was conducted by DNV (notified body).

Spiros Kotopoulis 1/18/23 Spiros Kotopoulis 1/18/23

DoMore Diagnostics announces expansion of the Scientific Advisory Board

DoMore Diagnostics announces Dr. Takayuki Yoshino, MD, Professor Hans-Joachim Schmoll, MD, Dr. Jakob Nikolas Kather, MD, and Dr. Marc Peeters, MD are joining the Scientific Advisory Board. The four leaders in GI oncology will undoubtedly make vital contributions in bringing the company forward.

Spiros Kotopoulis 12/7/22 Spiros Kotopoulis 12/7/22

DoMore Diagnostics announces successful integration with the Sectra software platform for digital pathology

DoMore Diagnostics today announced that its Histotype Px Colorectal outcome prediction marker is available on the Sectra pathology imaging platform, facilitating seamless and easy access to this cutting-edge technology.

Spiros Kotopoulis 8/12/22 Spiros Kotopoulis 8/12/22

Impressive results with The Histotype Px Colorectal cancer marker published in The Lancet Oncology

DoMore Diagnostics today announced that The Lancet Oncology has published an article documenting that the Histotype Px Colorectal algorithm even more accurately predicts patient outcomes when used in combination with tumor and lymph node status.

Spiros Kotopoulis 5/25/22 Spiros Kotopoulis 5/25/22

DoMore Diagnostics achieves CE-IVD mark for Histotype Px® Colorectal, an AI algorithm that predict patient outcomes in colorectal cancer patients by analyzing standard histology images

Spiros Kotopoulis 5/9/22 Spiros Kotopoulis 5/9/22

DoMore Diagnostics congratulates Prof. Håvard Danielsen with the King Olav V´s Cancer Research Prize for 2022

DoMore Diagnostics congratulates Prof. Håvard Danielsen with the King Olav V´s Cancer Research Prize for 2022. The prestigious prize was handed over by HM Kong Harald V on behalf of the Norwegian Cancer Society in Oslo on May 9.